Denil Nanji Shekhat - 01 Oct 2025 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: Director
Issuer ticker: MIRA
Reported as of: 01 Oct 2025
Net transaction value: +$30,210
SEC form: 4
Accepted by SEC: 03 Oct 2025, 20:00:18 UTC
Prior SEC filing: 10 Dec 2024
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Denil Shekhat

Key filing fact

Denil Nanji Shekhat filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 03 Oct 2025.

Key facts

This page summarizes Denil Nanji Shekhat's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Oct 2025, 20:00.

Change

Previous filing in this sequence was filed on 10 Dec 2024.
Current net transaction value: +$30,210.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002016605 Primary reporting owner

Shekhat Denil Nanji

Relationship: Director
Address: C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI
Signature: /s/ Denil Shekhat
Signature date: 03 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRA transaction

Common Stock

Award

Transaction value: $30,210
Shares: +22,378
Change %
Price: $1.35
Shares after: 22,378
Date: 01 Oct 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents 22,378 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc.